GYRE

In Q1 2026, Gyre Therapeutics reported a net loss of $9.9 million, with revenue of $22.5 million, leading to an 11.4% drop in shares. The company completed the acquisition of Cullgen Inc. for approximately $300 million. F351 received priority review status in China, and Gyre submitted an NDA for conditional approval. The CEO, Ying Luo, sold 10,136 shares. As of May 7, 2026, the stock price was $7.07, with a year-to-date decrease of 14.53% to 19.92%.